Literature DB >> 10210444

The effect of sildenafil on apomorphine-evoked increases in intracavernous pressure in the awake rat.

K E Andersson1, H Gemalmaz, K Waldeck, T N Chapman, J B Tuttle, W D Steers.   

Abstract

PURPOSE: The aim of this study was to develop a quantitative, awake animal model to investigate the effect of sildenafil on centrally-evoked erectile activity.
METHODS: Intracavernous pressures were recorded in awake, male Sprague Dawley rats after administration of apomorphine (100 or 250 microg./kg. subcutaneously). Sildenafil (100 microg./kg. intravenously) was then given 10 min. after a second dose of apomorphine. The time to first response, duration of response, and peak intracavernous pressure and area under the response, were measured before and after sildenafil.
RESULTS: Apomorphine produced rhythmic increases in intracavernous pressure. The pressure increase consisted of two components. The amplitude of the first, tonic response was 58 +/- 3 mm. Hg, and a superimposed, burst-like increase in pressure elevated this further to 81 +/- 6 mm. Hg. Bilateral transection of the pudendal nerves abolished the burstlike pressure changes; bilateral transection of the cavernous nerves prevented both responses. The duration of the apomorphine-induced increase in intracavernous pressure was significantly (p = 0.003) prolonged by sildenafil (100 microg./kg.) from 37 +/- 4 to 62 +/- 11 s (n = 6). The overall intracavernous pressure response to apomorphine (100 microg./kg.), measured as the area under the curve, was significantly (p = 0.003) increased by sildenafil (100 microg./kg.) from 67 +/- 8 to 142 +/- 31 units (n = 6). N-nitro-L-arginine methyl ester (40 mg./kg. intravenously) prevented the apomorphine-induced responses.
CONCLUSIONS: Monitoring intracavernous pressures in the awake rat represents a simple model to evaluate the effect of drugs on erectile function. Using this model we have shown that apomorphine elicits a rise in intracavernous pressure that can be prolonged by sildenafil. These results suggest that there may be a role for the combination of apomorphine and sildenafil in the management of erectile dysfunction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10210444

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

1.  Activation of central melanocortin receptors by MT-II increases cavernosal pressure in rabbits by the neuronal release of NO.

Authors:  R Vemulapalli; S Kurowski; B Salisbury; E Parker; H Davis
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

2.  Morphological and functional in vitro and in vivo characterization of the mouse corpus cavernosum.

Authors:  H Mizusawa; P Hedlund; A Håkansson; P Alm; K E Andersson
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

3.  Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats.

Authors:  Jorge D Brioni; Robert B Moreland; Marlon Cowart; Gin C Hsieh; Andrew O Stewart; Petter Hedlund; Diana L Donnelly-Roberts; Masaki Nakane; James J Lynch; Teodozyi Kolasa; James S Polakowski; Mark A Osinski; Kennan Marsh; Karl-Erik Andersson; James P Sullivan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-15       Impact factor: 11.205

Review 4.  A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?

Authors:  Konstantinos Hatzimouratidis; Dimitrios G Hatzichristou
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Future options for combination therapy in the management of erectile dysfunction in older men.

Authors:  Frank Sommer; Udo Engelmann
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 6.  Erectile dysfunction: expectations beyond phosphodiesterase type 5 inhibition.

Authors:  A Aversa; M Pili; A Fabbri; E Spera; G Spera
Journal:  J Endocrinol Invest       Date:  2004-02       Impact factor: 4.256

Review 7.  Animal models in urological disease and sexual dysfunction.

Authors:  Gordon McMurray; James H Casey; Alasdair M Naylor
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 8.  Combination therapy for erectile dysfunction: where we are and what's in the future.

Authors:  Ajay Nehra; Haluk Kulaksizoglu
Journal:  Curr Urol Rep       Date:  2002-12       Impact factor: 2.862

Review 9.  Oral and injectable medications for the treatment of erectile dysfunction.

Authors:  C C Carson
Journal:  Curr Urol Rep       Date:  2000-12       Impact factor: 2.862

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.